Debiopharm International SA and Arbor Pharmaceuticals, LLC Announce Their US Commercialization Partnership for Triptorelin in Central Precocious Puberty

Lausanne, Switzerland and Atlanta (ots/PRNewswire) -

Arbor Pharmaceuticals to commercialize triptorelin in
sustained-release formulation for the orphan indication central
precocious puberty

Debiopharm International SA (Debiopharm), part of Debiopharm
Group(TM), a Swiss-based global biopharmaceutical company, and Arbor
Pharmaceuticals, LCC (Arbor), a U.S.-based specialty pharmaceutical
company, jointly announce the execution of a distribution agreement
for the commercialization and promotion of triptorelin 22.5 mg in the
United States for central precocious puberty (CPP).

Under the terms of the agreement, Arbor acquires exclusive
commercial rights for triptorelin 22.5 mg in the U.S., for the CPP
indication. The product will be exported from Debiopharm Research and
Manufacturing SA to Arbor. Once approved, triptorelin 22.5 mg will be
made available primarily to pediatricians and pediatric
endocrinologists.

"We are delighted to be partnering with an excellent research
based company like Debiopharm to bring this important product to
pediatric patients in the United States," said Ed Schutter, President
and CEO of Arbor. "We are looking forward to working with them to
file this unique dosage form of sustained-release triptorelin with
the FDA in the near future."

"We are happy to have found a good partner to commercialize our
product in this orphan indication," said Thierry Mauvernay,
Co-President & Delegate of the Board of Debiopharm Group. "It is
important to us to make this treatment option with its 6-monthly
administration available to these young patients."

About Central Precocious Puberty (CPP)

GnRH-dependent CPP is defined by pubertal development occurring
before the age of 8 years in girls and 9 years in boys. It is
characterized by early pubertal changes such as breast development
and start of menses in girls and increased testicular and penile
growth in boys, appearance of pubic hair, as well as acceleration of
growth velocity and bone maturation, which often results in reduced
adult height and disproportioned body appearance due to premature
fusion of the growth plates. Reliable epidemiological data on CPP
worldwide are not available. The condition occurs in about 1 out of
every 5,000 to 10,000 children (leading to an estimated prevalence of
10,000 to 20,000 children in the USA). These numbers show that CPP is
a rare disease. Central precocious puberty is more common in girls
than in boys, with a female: male ratio estimated to be between 3:1
and 23:1.

About Triptorelin

Triptorelin is an agonist analogue of the natural
gonadotropin-releasing hormone (GnRH). Debiopharm has developed three
sustained-release formulations (1, 3 and 6 months) of triptorelin
pamoate. The 1-, 3- and 6-month formulations have been registered in
numerous countries in several indications.

About Debiopharm International SA

Debiopharm Group(TM) is a Swiss-based global biopharmaceutical
group of four companies active in drug development, GMP manufacturing
of proprietary drugs, diagnostics, and investment management.
Debiopharm International SA is focused on the development of
prescription drugs that target unmet medical needs. The company
in-licenses and develops promising drug candidates. The products are
commercialized by pharmaceutical out-licensing partners to give
access to the largest number of patients worldwide.

For more information, please visit http://www.debiopharm.com

We are on Twitter. Follow us @DebiopharmNews at
http://twitter.com/DebiopharmNews

About Arbor Pharmaceuticals, LLC

Arbor Pharmaceuticals, headquartered in Atlanta, Georgia, is a
specialty pharmaceutical company currently focused on the
cardiovascular, hospital and pediatric markets as well as generics
through its Wilshire division. The company has approximately 600
employees, with over 500 sales professionals that promote its
products to hospitals and physicians. In addition to its extensive
pipeline, the company continues to actively pursue growth through
acquisition or licensing of marketed or late-stage development
products. Arbor currently markets eighteen approved NDA and ANDA
products, and, along with Wilshire, has over forty products in
development. For more information regarding Arbor Pharmaceuticals or
any of its products, visit http://www.arborpharma.com or send email
inquiries to info@arborpharma.com

Debiopharm International SA Contact Christelle Tur Communication
Coordinator christelle.tur@debiopharm.com Tel: +41(0)21-321-01-11

Arbor Pharmaceuticals, LLC Contact Jason McCarthy CFO
jmccarthy@arborpharma.com Tel: +1-678-334-2423

Additional Media Contacts In London Maitland Chiara Valsangiacomo
cvalsangiacomo@maitland.co.uk Tel: +44(0)20-7379-5151

In New York Russo Partners, LLC Lena Evans Assistant Vice
President lena.evans@russopartnersllc.com Tel: +1-212-845-4262

ots Originaltext: Debiopharm Group
Im Internet recherchierbar: http://www.presseportal.de